Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5234960 | 0.94 | HIF1A (0.43) | HIF1AMMP2MMP9MMP12GAA | |
| Bromide SCHEMBL1582234 | 0.94 | HIF1A (0.43) | HIF1AMMP2MMP9MMP12GAA | |
| Bromide SCHEMBL6428595 | 0.92 | HIF1A (0.44) | HIF1AMMP2MMP9MMP12TSHR | |
| Iodide SCHEMBL13280558 | 0.91 | HIF1A (0.48) | HIF1AGAAL3MBTL1TSHRALDH1A1 | |
| Bromide SCHEMBL129506 | 0.87 | HIF1A (0.48) | HIF1AGAAL3MBTL1TSHRALDH1A1 | |
| Iodide SCHEMBL2414352 | 0.82 | HIF1A (0.40) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 | |
| Iodide SCHEMBL8182049 | 0.82 | HIF1A (0.40) | HIF1AGAAL3MBTL1ATMTSHR | |
| Iodide SCHEMBL8182047 | 0.82 | HIF1A (0.40) | HIF1AGAAL3MBTL1ATMTSHR | |
| SCHEMBL8373290 | 0.82 | HIF1A (0.43) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL8379392 | 0.82 | HIF1A (0.43) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025077841-A1 | AMIDE-SUBSTITUTED CYCLOALKYL COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USES THEREOF | 江苏恒瑞医药股份有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| CN-105531273-A | Bromodomain inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| CN-102884047-B | 2-pyridone compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-25 | — | — | CN | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-8207146-B2 | Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1089964-A1 | HYDRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000000465-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272630-A1 | Bromodomain Inhibitors | BRD4, BRDT, EP300 | HIF1A 2557/4885MMP2 1075/4885MMP9 958/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | HIF1A 2539/4885MMP2 1082/4885MMP9 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.